Regulatory Pathways for Rare Disease Clinical Trials in China

Introduction

Rare diseases affect an estimated 20 million people in China, yet historically these patients had limited access to innovative therapies. Clinical trials for rare diseases face unique challenges, including small patient populations, recruitment barriers, and limited disease registries. In recent years, the National Medical Products Administration (NMPA) has introduced regulatory pathways and incentives to encourage rare disease research, harmonizing with global best practices. China’s policy framework now includes expedited approvals, rare disease designation, and acceptance of multinational trial data. This article examines the regulatory pathways for rare disease trials in China, covering ethics, patient recruitment, global integration, and strategic considerations for sponsors.

Background and Regulatory Framework

Defining Rare Diseases in China

Unlike the U.S. Orphan Drug Act, China does not have a single statutory definition of rare diseases. Instead, the National Health Commission (NHC) publishes a “Rare Disease Catalog” that lists diseases qualifying for special regulatory support. The first catalog, published in 2018, included 121 diseases.

NMPA Rare Disease Pathways

The NMPA provides expedited review for drugs targeting catalog-listed rare diseases. Sponsors may apply for Breakthrough Therapy, Conditional Approval, or Priority Review status. These pathways shorten timelines and encourage investment in rare disease R&D.

Case Example: Spinal Muscular Atrophy Therapy

In 2019, a gene therapy for spinal muscular atrophy received conditional approval in China based on limited clinical data and strong unmet medical need. This case demonstrated the NMPA’s willingness to adopt flexible pathways for rare diseases.

Core Clinical Trial Insights

Patient Recruitment Challenges

Recruitment is constrained by small patient populations, lack of registries, and geographic dispersion. Sponsors often partner with patient advocacy groups and specialized Tier-1 hospitals to identify eligible patients. Decentralized trial models are increasingly explored to improve access for rural patients.

Ethical Considerations

Rare disease trials often involve pediatric populations or severely ill patients, requiring heightened ethical scrutiny. Informed consent must address risks, uncertainty, and long-term follow-up. Ethics committees review these protocols closely, sometimes extending timelines.

Role of Registries and Real-World Evidence (RWE)

China is expanding disease registries to support trial recruitment and long-term safety monitoring. RWE generated through registries and hospital networks is increasingly accepted by the NMPA to complement limited trial data, particularly in post-market settings.

Integration with Multinational Trials

The NMPA accepts multinational trial data if Chinese patients are included. This enables rare disease sponsors to leverage global development programs while meeting local regulatory requirements. Including 50–100 Chinese patients in a global trial can eliminate the need for separate bridging studies.

Compassionate Use and Expanded Access

China’s compassionate use programs allow patients with serious rare diseases to access investigational therapies before approval. While limited in scope, these programs demonstrate growing regulatory flexibility and patient-centeredness.

Pharmacovigilance and Long-Term Follow-Up

Rare disease therapies, especially gene and cell therapies, require intensive post-market safety monitoring. Sponsors must develop risk management plans (RMPs) with long-term follow-up protocols to satisfy NMPA expectations.

Best Practices & Preventive Measures

Sponsors should partner early with advocacy groups, establish collaborations with Tier-1 hospitals, and explore decentralized trial models for broader patient access. Regulatory engagement is critical to clarify expectations for trial design, patient numbers, and data acceptance. Building registries and integrating RWE strengthens submissions and accelerates approval.

Scientific & Regulatory Evidence

China’s rare disease policies align with ICH E6(R2) GCP, ICH E17 MRCT guidelines, and WHO principles. The Rare Disease Catalog and 2019 Drug Administration Law underpin China’s approach, while conditional approvals mirror FDA accelerated approval and EMA PRIME programs. These frameworks demonstrate convergence with global regulatory practices.

Special Considerations

Pediatric patients represent a large proportion of rare disease populations, requiring tailored protocols, dosing studies, and informed consent procedures. HGRAC approval is mandatory when genetic resources are involved, adding another compliance layer. Sponsors must balance speed with ethical rigor in designing rare disease trials.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult the NMPA and HGRAC early in protocol development for rare disease trials. Regulatory advice clarifies expectations for patient numbers, trial designs, and genetic data use. Early consultation with ethics committees ensures protocols address pediatric and vulnerable populations appropriately.

Case Studies

Case Study 1: Pediatric Rare Disease Trial

A multinational sponsor conducted a pediatric rare disease trial at Tier-1 hospitals in Beijing and Shanghai. By partnering with patient advocacy groups and including 80 Chinese patients in the global trial, the sponsor avoided a separate bridging study and achieved NMPA approval within 12 months.

Case Study 2: Gene Therapy Conditional Approval

A domestic biotech company developed a gene therapy for a catalog-listed rare disease. With limited Phase II data but strong unmet need, the NMPA granted conditional approval, requiring post-market RWE studies. This case illustrated regulatory flexibility in balancing urgency with safety.

FAQs

1. What qualifies as a rare disease in China?

Diseases listed in the National Health Commission’s Rare Disease Catalog qualify for regulatory incentives and expedited pathways.

2. Does China have orphan drug legislation?

Not formally, but the Rare Disease Catalog and NMPA expedited pathways provide orphan drug-like benefits.

3. How does China support rare disease recruitment?

Through registries, advocacy partnerships, and inclusion of rare disease centers in Tier-1 hospitals, though recruitment remains challenging.

4. Can multinational trial data be used in China?

Yes, if Chinese patients are included. Adequate representation reduces the need for bridging studies.

5. What is the role of RWE in rare disease trials?

RWE complements limited trial data, supports post-market commitments, and is increasingly accepted by the NMPA.

6. What are the main regulatory pathways for rare diseases?

Breakthrough Therapy, Conditional Approval, and Priority Review are available for drugs targeting rare diseases in the catalog.

Conclusion & Call-to-Action

China’s regulatory pathways for rare disease trials have evolved rapidly, providing expedited approvals, data flexibility, and patient access programs. For sponsors, success requires early engagement with regulators, robust patient recruitment strategies, and collaboration with advocacy groups. Organizations planning rare disease trials in China must integrate NMPA requirements, HGRAC approvals, and global harmonization principles to accelerate development and deliver innovative therapies to patients in need.